About this trial
The goal of this study is to determine if viral infection with the common cold leads to an exacerbation in participants with bronchiectasis. The investigators will compare the participants with bronchiectasis to a group of healthy participants. The main questions it aims to answer are:
* Does viral infection with the common cold lead to an exacerbation in bronchiectasis? * Does the immune response differ to that of a healthy participant?
Participants will attend for a screening visit to see if they are eligible. All participants who are eligible and have consented to take part will have baseline investigations done including blood tests and a bronchoscopy. They will be given a spray of a virus that causes the common cold into their nose. They will then be followed up over the next 6 weeks with some of the following procedures at each study visit; spirometry, nasosorption, nasal lavage, nasal brushing, blood test, sputum collection and a bronchoscopy. Participants will be asked to keep a daily record of their symptoms throughout the study.
Eligibility criteria
Qualifiers
Confirmed diagnosis of bronchiectasis aged 18-65 years with bronchiectasis severity index score of 0-8 .
For Pseudomonas colonised individuals, isolation of Pseudomonas aeruginosa in two or more cultures, at least 3 months apart in a 2-year period.
Disqualifiers
Any medical co-morbidity impacting the study in the opinion of the medical team
Current smoking history within last 12 months or ex smoking history >5 pack years
Pre-existing serum neutralising antibodies to RV-A16 (strain to be used for challenge)
Close contact with infants or elderly individuals either at home or workplace
Trial design
Treatments tested in this trial
- Rhinovirus A-16 Infection
Treatment groups
Sponsors and collaborators
Imperial College London
Lead sponsor
Imperial College Healthcare NHS Trust
Collaborator